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This study sought to determine whether the presence of hypermethylated genes in the surgical margins can predict local recurrences
in head and neck squamous cell carcinomas (HNSCCs). We prospectively collected tumour and surgical margin specimens from
patients with HNSCCs who had undergone surgical resections. Quantitative methylation-specific PCR (QMSP) of CDKN2A,
CCNA1 and DCC were performed in these specimens and correlated with clinical data. Of the 42 patients eligible for the study,
27 were hypermethylation informative for the above three genes. This latter group was associated with longer disease-free survivals
(P¼0.007) and longer time to disease-specific deaths (P¼0.004). Multivariate analyses confirmed hypermethylation non-informative
tumours as an independent prognosticating factor for disease-specific deaths (risk ratio 3.8, P¼0.026). Quantitative MSP of the
margins of 24 hypermethylation informative tumours revealed that 11 patients had molecularly positive margins, of which, five
developed disease-specific events (DSEs, three local recurrences and two metastases), compared to none in patients with
molecularly negative margins, after a median follow-up of 48 months. Log-rank analyses showed that molecularly positive margins
were associated with shorter time to local recurrences and disease-specific deaths (P¼0.03 and 0.01, respectively). This study
demonstrated that QMSP of hypermethylated promoters in surgical margins predicted all the local recurrences in our series of
HNSCC patients. We have also identified hypermethylation non-informative tumours as an independent predictor for the
development of DSEs.
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Head and neck squamous cell carcinoma (HNSCC) afflicts more
than 500000 patients per year (Parkin et al, 2005). Despite recent
advances in therapeutic options, the mortality remains about 50%
in 5 years. This is in part due to the high incidence of local
recurrences (up to 50%) after surgery despite achieving histo-
pathologically clear resection margins (Jesse and Sugarbaker, 1976;
Davidson et al, 1981; Kowalski et al, 1993). Two possible
mechanisms could account for these observations (Hockel and
Dornhofer, 2005). First, minimal residual cancer cells might
remain undetectable by standard histological margin assessment
(Brennan et al, 1995; van Houten et al, 2004) and second, local
recurrences may have evolved from a field of genetically altered
mucosal cells (Slaughter et al, 1953; Califano et al, 1996; van
Houten et al, 2004; Braakhuis et al, 2005; Martone et al, 2007). The
detection of these ‘high risk’ lesions will allow clinicians to tailor
adjuvant therapeutic options that can diminish the incidence of
recurrences.
The improved understanding of tumour biology has uncovered
many novel tumour markers that can distinguish between
malignant and non-malignant cells (Sidransky, 2002). Brennan
et al, (1995) first reported the use of TP53 mutation for the
detection of the residual tumour cells in surgical resection margins
to predict locoregional recurrences. Various groups have also
investigated surgical margins with other molecular markers such
as eIF4E, PSA, tyrosinase and microsatellite instability to predict
locoregional recurrences (Proebstle et al, 1996; Theodorescu et al,
1999; Sardi et al, 2000; Nathan et al, 2002; Temam et al, 2004).
More recently, silencing of tumour suppressor genes by
hypermethylation of selected promoter regions has been identified
as an important mechanism of carcinogenesis and implicated in a
variety of solid and haematological malignancies (Laird and
Jaenisch, 1994; Esteller et al, 2002; Momparler, 2003). As
hypermethylated promoters often occur from 100- to 1000-folds
more frequently in tumour cells compared to normal cells, they are
therefore good candidate molecular markers for detection of low
numbers of tumour cells in the milieu of normal cells (Laird, 2003).
Methylation-specific PCR (MSP) and quantitative MSP (QMSP)
have been used to detect methylated DNA in the body fluids of
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spatients with cancers of the breast (Silva et al, 1999, 2002), lung
(Esteller et al, 1999), prostate (Goessl et al, 2000), bladder
(Dominguez et al, 2002), gastrointestinal tract (Kawakami et al,
2000; Eads et al, 2001; Zou et al, 2002) and head and neck region
(Sanchez-Cespedes et al, 2000; Righini et al, 2007). There are
however few reports of methylation analyses of resection margins.
Goldenberg et al, (2004) demonstrated in a pilot study with six
patients that intra-operative assessments of surgical margins
methylation status were feasible using QMSP. No recurrence was
observed in any of the three patients with positive molecular
resection margin but the follow-up period was short. Shaw et al,
(2007b) performed quantitative methylation analyses of resection
margins in 20 patients using pyrosequencing methylation analyses
(PMA) . However, 6 out of 13 positive margins subsequently
developed locoregional recurrences, there were however two
recurrences in seven negative margins. The authors suggested
that the small sample size and the use of fixed tissue DNAs may
have contributed to the inconclusive findings. Furthermore, the
use of pyrosequencing with a sensitivity of 1 out of 20 to 1 out of
50 may not be appropriate for detection of small numbers of
tumour cells in surgical margins. Most recently, Martone et al,
(2007) identified similar methylation profiles between tumours
and margins in 9 out of 11 patients with HNSCC-specific deaths.
As this study consisted only of retrospectively selected patients
who had relapses and HNSCC-specific deaths but no disease-free
controls, it did not identify significant association between
methylation statuses in surgical margins with disease-free
survivals.
The objective of our study was to measure the amount of
hypermethylated promoters of selected genes, in a series of
prospectively collected surgical margins of HNSCC patients, to
predict local recurrences and cancer-specific survivals. We utilised
QMSP to interrogate the methylation profiles of CDKN2A, CCNA1
and DCC in the resection margins in a cohort of patients who
underwent curative resections of HNSCCs. We selected these genes
on the basis of reports that CDKN2A (Shaw et al, 2006), CCNA1
(Shaw et al, 2006) and DCC (Carvalho et al, 2006) are
hypermethylated in 28, 53 and 75% of HNSCCs respectively.
Significantly, all three genes have very low level of methylation in
normal mucosa and are thus good candidate genes for the purpose
of our study. Functionally, CDKN2A (Kim and Sharpless, 2006)
and DCC (Mehlen and Fearon, 2004; Carvalho et al, 2006) are
known tumour suppressor genes, whereas CCNA1 (Ji et al, 2005)
has been shown to play a role in cell cycle regulation. The study
was conducted in two phases: (1) to determine the hypermethyla-
tion informative statuses of the primary tumours and (2) to detect
the presence of promoter hypermethylation in the surgical margins
of those tumours that were hypermethylation informative; all
findings were then correlated with clinical data.
MATERIALS AND METHODS
Sample collection and histopathological examination
We prospectively collected fresh frozen tumour biopsies and
surgical margin specimens from patients treated for HNSCCs at
Institut Gustave-Roussy (Villejuif, France) between January and
December 2000. The Institutional Review Board approved the
study, and informed consent was obtained from all patients.
Tumour staging (TNM and pTNM) was performed according to
the Union International Contre Cancer 1997 criteria. The study
design, samples collection and histopathological examinations of
surgical specimens were performed as previously described
(Temam et al, 2004).
Patients with close resection margins (p5mm) on surgical
specimens or moderate-to-severe dysplasia on surgical margins
were excluded. To ensure adequate representation of the margins,
patients with less than three margins available were excluded from
the second phase of the study.
During the study period, 42 patients met the inclusion criteria
and were recruited for the study. All patients underwent as first
treatment surgical resection of the primary tumours and unilateral
or bilateral neck dissections depending on tumour sites and nodal
status. The indication for postoperative radiotherapy depended on
tumour stage, tumour site and nodal status.
DNA extraction and bisulphite treatment
All tumour biopsy specimens included in the analysis were
diagnosed as invasive HNSCCs. Serial 40-mm thick frozen sections
of each tumour or surgical margin specimen were performed with
H&E staining for histopathologic control of the first and the last
5-mm thick section. A pathologist (PF), blinded to the clinical data,
reviewed all the slides to confirm (1) the percentage of tumour
cells present in the tumour biopsies or (2) the absence of
carcinomas or moderate-to-severe dysplasias in each surgical
margin.
DNA from tumour and surgical margin specimens was extracted
using the QIAamp Tissue kit (Qiagen, Courtaboeuf, France). DNA
quality was verified using GeneQuant II (Amersham Pharmacia
Biotech, Cambridge, UK).
The extracted DNA was modified by sodium bisulphite in
accordance to the manufacturer’s protocol (Chemicon no. 7280)
and resuspended in 100ml of TE buffer (EDTA 2.5mmoll
 1 and
Tris-HCl 10mmoll
 1) and stored at  201C.
Methylation analysis
The bisulphite-modified DNA was used as a template for QMSP, as
previously described (Harden et al, 2003) with some modifications.
In brief, the primers and probes were designed to specifically
amplify the bisulphite-converted promoter of the gene of interest.
The primers and probe sequences for CDKN2A and b-actin have
been previously described (Lo et al, 1999; Harden et al, 2003). The
sequences of CCNA1 and DCC are listed below in the order of
forward primer, reverse primer and probe: CCNA1; 50-GCGGTTT
CGGAGAGCGTAC-30,5 0-GACGCCCCCGAACCTAAC-30, 6FAM50-
TTTGTCGCGGTCGGTATGGAAACG-30TAMRA, DCC; 50-TGTTCG
CGATTTTTGGTTTC-30,5 0-ACCGATTACTTAAAAATACGCG-30,
6FAM50-TTTTCGGAGTTTTTTTGTTTAGCGC-30TAMRA.
Fluorogenic PCRs were carried out in a reaction volume of 50ml
consisting of 300nM of each primer; 150nM of probe. 10mlo f
treated DNA solution were used in each real-time MSP reaction.
Amplifications were carried out in 96-well plates in a 7900
Sequence Detector System (Perkin-Elmer Applied Biosystems,
Norwalk, CT, USA). Commercially available methylated DNA
(CpGenome Universal Methylated DNA AbCys S.A. no. S7821)
were used as positive controls and serial dilutions of this DNA
were used for constructing the calibration curves to detect between
five genomic equivalents and 15000 genomic equivalents of DNA
on each plate. Identical laboratory procedures and intermixing
were performed in the same laboratory for each batch tested. All
tumours and margins DNA for each test batch were bisulphite
modified at the same time with their positive and negative controls
to minimise variations in experimental conditions. All plates
contained multiple water blanks and bisulphite modified Human
Genomic DNA (CpGenome Universal Unmethylated DNA
no. S7822) as negative controls. Every QMSP was performed in
duplicates or triplicates.
Calculation of methylation index and weighted tumour
methylation index
Methylation index (MI) was computed as the ratios between the
methylation values of the gene of interest and the internal
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sreference gene, b-actin, which were obtained by Taqman analysis
(Harden et al, 2003). These ratios were used as measures to
represent the relative levels of methylation in any given sample:
MI¼gene of interest methylation value/b-actin methylation
value  100%.
Given that tumour specimens comprised between 50 and 100%
of malignant cells, the MI obtained from tumour specimens
therefore represented the average methylation levels of a mixture
of the normal and malignant cells. As methylation of CDKN2A,
CCNA1 and DCC exist only in very low levels in normal cells
(Carvalho et al, 2006; Shaw et al, 2006), we calculated a separate
index, which we termed as the weighted tumour methylation index
(WTMI) to better reflect methylation levels in the tumour cells:
Weighted tumour methylation index (WTMI)¼MI of the
tumour specimens divided by the percentage of malignant cells
present in the tumour specimens (MI/percentage of tumour
 100%).
Stratification of tumours and margins In contrast to the
semiquantitative nature of MSP, QMSP generates precise MI in
continuous variables and thus necessitates that a threshold be set
to dichotomise the data. We employed two thresholds to stratify
(a) tumours into hypermethylation informative or non-informa-
tive using WTMI of the tumour specimens and (b) margins into
molecularly positive or negative using MI of the margin specimens:
Stratification of tumours. Tumours were assigned to be
hypermethylation informative only if WTMI are X5%. The cutoff
at 5% was chosen to select only tumours that have very high levels
of hypermethylation to allow discriminative detection of very small
numbers of informative tumour cells mixed in a large numbers of
normal cells in the surgical margins.
Stratification of margins. Quantitative MSP for the margins were
performed only on the tumours that were hypermethylation
informative and only on the genes that the tumours were
informative for. We then ranked the margins in ascending order
according to the MI obtained for each of the gene tested. The
margins with MI above the 90th percentile of all the margins tested
for that gene were deemed molecularly positive for that
corresponding gene. This threshold was set to allow exclusions
of margins with low levels of MI of unknown significance.
Statistical analysis
This prospective study was powered based on a previous study
conducted by one of our co-authors (Temam et al, 2004), which
demonstrated an disease-free survival (DFS) at 30 months of 85%
among patients with negative margins and 30% among patients
with positive margins (using microsatellite instability as markers).
To achieve a study with 80% power, we calculated prospectively
that 22 informative patients were required to demonstrate a similar
difference in DFS at 30 months with an a-risk of 5%, working on
the basis that half of the informative patients have positive margins
for hypermethylation in our study. Univariate analyses using
Fisher’s exact test and Student’s t-test were performed for
categorical and continuous data, respectively. Clinical and
biological characteristics were analysed for their association with
time to local recurrence using Cox proportional hazards models.
Estimates of survival curves were calculated according to the
Kaplan–Meier product-limit method and were calculated from the
time of surgery to the time of death or the last follow-up visit.
Times to local recurrence for various prognostic groups were
compared using the log-rank test. The Cox proportional hazards
regression model was used to assess the prognostic effect of patient
characteristics and molecular markers to estimate DFS and time to
disease-specific death. Predictive variables with P-values of p0.10
for the univariate Cox proportional hazards model were included
in a multicovariate model. All of the computations carried out
were performed using NCSS and SPSS software.
RESULT
Methylation profiles of tumours
Quantitative MSP of the three selected genes CDKN2A, CCNA1 and
DCC was performed on 42 tumours. High levels of hypermethyla-
tion (WTMI X5%, range 5.1–95%) were detected in one or more
of the three genes in 64.3% (n¼27/42) of tumours. These were
designated as hypermethylation informative as described (Materials
and Methods). Baseline clinical characteristics such as age, sex,
site, stage, histopathological gravity signs and adjuvant therapy did
not differ significantly according to the tumour methylation
profiles (Table 1). The median clinical follow-up period was 48
months (range, 1–89). Only three patients were lost to follow-up
within 24 months of diagnosis. Mean follow-up period for patients
who remained events free were 70 months. Sixteen patients
developed one or more disease-specific events (DSEs, defined as
local and/or regional recurrences and/or distant metastasis) with
median DFS of 12.25 months (range, 1–53). The hypermethylation
informative group fared better, compared to the non-informative
group; with longer DFSs and longer time to disease-specific deaths
(P¼0.007 and 0.004, respectively, Kaplan–Meier analysis with
log-rank test) as shown in Figure 1. Multi-covariate analyses with
possible confounding factors such as age, sex, site, stage,
histopathological gravity signs and adjuvant therapy identified
Table 1 Patient characteristics according to tumour methylation status
Tumour hypermethylation
Informative
(n¼27)
a
Non-informative
(n¼15) P-value
b
Age, years
Mean±s.d. 59.67±9.7 57.07±10.46
Median (maximum,
minimum)
61 (32, 77) 61 (39, 73) 0.72
Sex, n (%)
Male 22 (81.5) 12 (80)
Female 5 (18.5) 3 (20) 1
Site, n (%)
Oral cavity 10 (37.0) 6 (40.0)
Oropharynx 10 (37.0) 2 (13.3)
Hypopharynx 5 (18.5) 3 (20.0)
Larynx 2 (7.4) 4 (26.7) 0.218
Tumour stage, n (%)
I–II 8 (29.6) 2 (13.3)
III–IV 19 (70.4) 13 (86.7) 0.286
Histopathological gravity signs
c, n (%)
No 24 (88.9) 10 (66.7)
Yes 3 (11.1) 5 (33.3) 0.11
Adjuvant therapy
d, n (%)
No 14 (51.9) 12 (80.0)
Yes 13 (48.1) 3 (20.0) 0.102
Disease-specific events, n (%)
No 20 (74.1) 6 (40.0)
Yes 7 (25.9) 9 (60.0) 0.047
Disease-specific death, n (%)
No 22 (81.5) 6 (40.0)
Yes 5 (18.5) 9 (60.0) 0.015
aInformative: high level of gene promotor hypermethylation (WTMI X 5%).
bFisher’s
exact test.
cHistopathological gravity signs: perineural invasion, angiolymphatic
invasion or both.
dConcurrent chemoradiotherapy or radiotherapy alone.
Margins hypermethylation predict HNSCC recurrences
HK Tan et al
359
British Journal of Cancer (2008) 99(2), 357–363 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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prognosticating factor for DFS with a risk ratio of 3.82 (Table 2).
Molecular analyses of surgical margins
In the second phase of this study, we performed QMSP on the
resection margins of the hypermethylation informative tumours.
Three patients with informative tumours were excluded from this
phase because there were less than three margins available for
analysis (Materials and Methods). One hundred-thirteen margins
from the remaining 24 patients (3–7 margins per patient)
underwent QMSP analyses for the genes that were informative in
the primary tumours. The majority of the margins had very low
methylation levels for CDKN2A, CCNA1 and DCC, with median MI
at 0.08% (range 0–0.39%), 0.06% (range 0–31.9%) and 0.08%
(range 0–2.28%), respectively. The threshold MI levels for defining
margins molecular positivity, set at 90th percentile for each of the
gene tested, were 0.36% (CDKN2A), 0.87% (CCNA1) and 0.91%
(DCC). Twelve margins from 11 patients were deemed molecularly
positive; 10 patients had one margin that were positive for one or
more gene tested, whereas one other patient had two margins that
were positive for the same gene.
Baseline clinical characteristics did not differ according to
margins methylation status (Table 3). Five of the 11 patients with
molecularly positive surgical margins developed DSE (three local
recurrence, two distant metastases) compared to none in the 13
patients with molecularly negative surgical margins (P¼0.011,
Fisher’s exact test).
The local recurrences occurred in two oropharyngeal cancers
(stage IV) and one oral cavity cancer (stage II). The distant
metastases were both lung metastases and had occurred in one oral
cavity cancer (stage II) and one oropharyngeal cancer (stage IV).
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Figure 1 Kaplan–Meier curve of hypermethylation informative tumour vs hypermethylation non-informative tumour in (A) disease-free survival and (B)
time to disease-specific death.
Table 2 Univariate and multivariate Cox proportional hazards models in
estimating time to disease-specific death
Covariates
Regression
coefficient s.e.
Risk
ratio Probability
Age, years  0.014 0.025 0.986 0.567
Sex (male vs female) 0.813 0.758 2.254 0.284
Stage (I–II vs III–IV) 0.012 0.667 1.012 0.985
Adjuvant therapy
a (yes vs no) 0.306 0.548 1.358 0.577
Histopathological gravity sign
(yes vs no)
0.377 0.602 1.458 0.531
Hypermethylation informative
(  vs +)
1.341 0.602 3.823 0.026
b
aConcurrent chemoradiotherapy or radiotherapy alone.
bNo covariate other than
tumour methylation status was entered in the multivariate analyses, because P40.10
for all other covariates.
Table 3 Patient characteristics according to margin methylation status
Margin hypermethylation
+   P-value
a
Age, years
Mean±s.d. 61.6±11.1 58.3±9.7
Median (maximum, minimum) 64 (40, 77) 61 (32, 68) 0.72
Sex
Male 8 (72.7) 12 (92.3)
Female 3 (27.3) 1 (7.7) 0.3
Site, n (%)
Oral cavity 6 (54.5) 4 (30.8)
Oropharynx 5 (45.5) 4 (30.8)
Hypopharynx 0 (0) 4 (30.8)
Larynx 0 (0) 1 (7.7) 0.15
Tumour stage, n (%)
I–II 4 (36.4) 3 (23.1)
III–IV 7 (63.4) 10 (76.9) 0.67
Histopathological gravity signs
b, n (%)
No 9 (81.8) 12 (92.3)
Yes 2 (18.2) 1 (7.7) 0.58
Adjuvant therapy
c, n (%)
No 4 (36.4) 7 (53.8)
Yes 7 (63.4) 6 (46.2) 0.17
Disease-specific event, n (%)
No 5 (45.5) 13 (100)
Yes 6 (54.5) 0 (0) 0.01
Locoregional recurrence, n (%)
No 8 (72.7) 13 (100)
Yes 3 (27.3) 0 (0) 0.03
d
Disease-specific death, n (%)
No 7 (63.4) 13 (100)
Yes 4 (36.4) 0 (0) 0.01
d
aFisher’s exact test.
bHistopathological gravity signs: perineural invasion, angiolym-
phatic invasion or both.
cConcurrent chemoradiotherapy or radiotherapy alone.
dLog-rank test.
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associated with decreased time to local recurrences (P¼0.03,
Kaplan–Meier analysis with log-rank test, Figure 2A). The latter
was not significantly associated with other covariates (age, sex,
site, stage, histopathological gravity signs and adjuvant therapy) by
Cox regression analysis (not shown). Furthermore, molecularly
positive surgical margins were associated with decreased time to
disease-specific deaths (P¼0.013, Kaplan–Meier analysis with
log-rank test, Figure 2B).
DISCUSSION
The objective of our study was to measure the relative amount of
hypermethylated promoters of selected genes in the surgical
margins of HNSCC patients and to determine whether these could
predict local recurrences and cancer-specific survivals. The most
important finding in our study is that the molecularly positive
margins identified by QMSP correctly predicted all five DSE (three
local recurrences and two distant metastases), whereas none of the
patients with molecularly negative margins developed any DSE at a
median follow-up period of 48 months.
WTMI and prognosis
Sixty-four per cent of the HNSCCs in our cohort of patients were
informative for hypermethylation. This compares favourably with
the ratio of informative tumour using other molecular markers
such as TP53 mutation (50% informative) (Boyle et al, 1993;
Brennan et al, 1995) and MSI (48% informative) (Temam et al,
2004). We noted that tumour stage was not associated with
recurrence in this series, probably because we selected patients
after exhaustive pathological assessments or because the sample
size was small for subset analyses.
Our findings that patients with hypermethylated tumours have
better prognosis corroborated with recent reports of others. A
recent study reported promoter methylation profiles of hMLH1,
MGMT and CDKN2A in 51 cases of HNSCCs using MSP and
demonstrated that tumours with two or more methylated genes
had improved DFS at 2 years (Puri et al, 2005). Koscielny et al,
(2007) reported in his series of 67 patients that hypermethylation
and LOH were the two main mechanisms responsible for
inactivating CDKN2A but only the hypermethylated group were
associated with a lower incidence of locoregional recurrence. Shaw
et al, (2007a) observed in a series of 76 patients that tumours with
CpG island methylation phenotype (CIMP) were associated with
marked inflammatory response and less aggressive tumour
biology. These reports and our findings in this study are emerging
evidence that hypermethylation of certain genes in HNSCCs may
be associated with longer survival. Unfortunately, available
literature does not provide clear insight to the mechanism behind
this counter-intuitive observation that hypermethylation of
tumour suppressor genes in HNSCCs can lead to better prognosis.
Nevertheless, a possible parallel mechanism can be drawn from
studies in colorectal cancers. There is convincing evidence that
CIMP and chromosomal instability represent two independent and
inversely related mechanisms of genetic and epigenetic instability
in sporadic colorectal carcinomas (Goel et al, 2007). Furthermore,
CIMP underlies a subtype of colorectal cancer with microsatellite
instability with distinctive clinical features (Ribic et al, 2003;
Weisenberger et al, 2006). We postulate that a similar mechanism
may be at work in HNSCCs, where hypermethylated tumours
constitute a subgroup of HNSCCs with a distinctive clinical profile.
The possible presence of LOH in CDKN2A (Koscielny et al,
2007) and DCC (Papadimitrakopoulou et al, 1998) may increase
the likelihood of tumours being non-informative for these two
markers. However, this is unlikely to confound our findings in the
margin analyses of informative tumours. Furthermore, the absence
of data that clearly outline the interaction between LOH and
hypermethylation has made it difficult to adjust our scoring
system to cater for the presence of LOH.
MI of surgical margins and recurrence
All three local recurrences and two distant metastases occurred in
the 11 (out of 24) patients with molecularly positive margins. We
noted that 7 out of the 11 patients with molecularly positive
margins underwent adjuvant radiotherapy and, of these, only one
patient developed local recurrence. In contrast, of the remaining
four patients who did not have adjuvant radiotherapy therapy, two
had developed local recurrences. It is likely that adjuvant
treatments have prevented local recurrences that might have
otherwise occurred in some of these patients with molecularly
positive margins and thus may partly account for the ‘false-
positive’ patients.
In contrast, all 13 patients with molecularly negative margins
turned out to be true negative. We noted that four of these were
hypopharyngeal tumours (often associated with the poorest
prognosis), while there was none in the group with positive
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Figure 2 Kaplan–Meier curves of margin molecularly positive vs margin molecularly negative in (A) time to local recurrence and (B) time to disease-
specific death.
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smargins. Although this disparity in tumour sites did not reach
statistical significance (P¼0.067, Fisher’s exact test), probably due
to the small sample size, we were nonetheless reassured that the
specificity of the molecularly negative margins could not be
attributed to the selection of tumour sites with favourable
prognosis.
Implication
Our findings have both clinical and scientific implications to
HNSCCs. Clinically, the poorer prognosis of patients with non-
informative tumours or molecularly positive surgical margins may
warrant either closer follow-up or recommendation of adjuvant
therapy, even in the absence of other risk factors such as advanced
stage, perineural invasion and perivascular invasion. Conversely,
in cases where the benefit of adjuvant therapy is equivocal,
methylation profiles of the tumours or the margins can serve as
additional indicators to tailor sensible treatment strategies so as to
minimise unnecessary treatment morbidities. However, these
results must be verified in an independent prospective study
before it can be used to formulate clinical guidelines. We are in the
process of incorporating such a validation study into an ongoing
international, multicentric, prospective controlled trial led by
Institute Gustave-Roussy.
For any tumour molecular marker to be clinically relevant, it
should ideally be informative in the majority of that specific
tumour. In previous reports of similarly designed studies,
molecular markers such as TP53 and MSI were both informative
in about 50% of HNSCCs. In comparison, hypermethylation was
informative in almost two-thirds of the HNSCCs using our panel of
three genes, even though we only designated tumours with very
high level of hypermethylation as informative. The percentage of
informative tumours can conceivably be further increased by
screening other suitable candidate genes. Hypermethylated genes
are therefore good molecular markers for HNSCCs in the clinical
settings.
Scientifically, our findings together with other reports would
suggest that hypermethylation of certain gene loci may confer a
tumour phenotype with distinctive clinical characteristics. Further
research is warranted to delineate the exact roles of hypermethyla-
tion and other alternative mechanisms such as genetic deletion and
point mutation in HNSCC carcinogenesis.
This study also illustrates that QMSP is ideally suited for
detection of hypermethylated markers in surgical margins. It
detects promoter hypermethylation with great sensitivity and
specificity. In addition, it is technically robust and easily
reproducible. Most importantly, it offers significant advantage to
conventional MSP because of its ability to generate accurate
quantitative data as a continuous variable. The latter allows the
dichotomy of data at a threshold to facilitate stratification, a
feature that we leverage on to determine the tumour methylation
profile (hypermethylation informative vs non-informative) and the
margin methylation status (molecularly positive vs negative).
Summary
This is to our knowledge the first study to report that presence of
hypermethylated promoters in surgical margins of HNSCCs can
predict local recurrences and disease-specific deaths. Performing
QMSP with a panel of three genes (CDKN2A, CCNA1 and DCC),
we found 64% of HNSCC tumours were hypermethylation
informative. Methylation analyses of their resection margins
correctly predicted all the recurrences in this cohort of patients.
Furthermore, we have showed that HNSCCs with hypermethyla-
tion of these three gene promoters have a better prognosis.
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